File(s) not publicly available
Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians
journal contribution
posted on 2023-02-01, 02:43 authored by P R Asih, P Chatterjee, G Verdile, Veer GuptaVeer Gupta, R D Trengove, R N MartinsA beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the 'amyloid hypothesis', the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance its clearance. Some have progressed to human trials, however all have failed to improve cognition in patients. This has led researchers to question whether Aβ is really the problem. However, the trials have been targeting end stages of AD, by which stage extensive irreversible neuronal damage has already occurred. Intervention is required preclinically, therefore preclinical AD biomarkers are needed. In this regard, amyloid imaging and cerebrospinal fluid biomarkers are leading the way, with plasma biomarkers and eye tests also being investigated. This review covers the current state of knowledge of Aβ as an early diagnostic biomarker and as a therapeutic target in AD.
History
Journal
Neurodegenerative disease managementVolume
4Pagination
363 - 378Publisher DOI
eISSN
1758-2032Publication classification
C1.1 Refereed article in a scholarly journalUsage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicineClinical NeurologyNeurosciences & Neurologyamyloidanti-amyloid drugbiomarkersCSFlifestylePET amyloid imaging plasma biomarkersretinal photographyType 2 diabetesA-BETACOGNITIVE DECLINECEREBROSPINAL-FLUIDAPOLIPOPROTEIN-EDISEASE RISKDEMENTIAMECHANISMSCLEARANCEPEPTIDE
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC